These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 25981142)

  • 1. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation.
    Skeppholm M; Al-Aieshy F; Berndtsson M; Al-Khalili F; Rönquist-Nii Y; Söderblom L; Östlund AY; Pohanka A; Antovic J; Malmström RE
    Thromb Res; 2015 Jul; 136(1):148-53. PubMed ID: 25981142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.
    Al-Aieshy F; Malmström RE; Antovic J; Pohanka A; Rönquist-Nii Y; Berndtsson M; Al-Khalili F; Skeppholm M
    Eur J Clin Pharmacol; 2016 Jun; 72(6):671-9. PubMed ID: 27066956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
    Barrett YC; Wang Z; Frost C; Shenker A
    Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
    Skeppholm M; Hjemdahl P; Antovic JP; Muhrbeck J; Eintrei J; Rönquist-Nii Y; Pohanka A; Beck O; Malmström RE
    Thromb Res; 2014 Oct; 134(4):783-9. PubMed ID: 25172669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.
    Gouin-Thibault I; Flaujac C; Delavenne X; Quenet S; Horellou MH; Laporte S; Siguret V; Lecompte T
    Thromb Haemost; 2014 Feb; 111(2):240-8. PubMed ID: 24172843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: Experience at a single institution.
    Park SH; Seo YH; Park PW; Kim KH; Seo JY; Lee HT; Kwoun WJ; Ahn JY
    J Clin Lab Anal; 2019 Jun; 33(5):e22869. PubMed ID: 30860622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
    Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
    Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation.
    Miklič M; Mavri A; Vene N; Söderblom L; Božič-Mijovski M; Pohanka A; Antovic J; Malmström RE
    Eur J Clin Pharmacol; 2019 Aug; 75(8):1069-1075. PubMed ID: 31139866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of apixaban anti-factor Xa assay and impact of body weight.
    Wasan SM; Feland N; Grant R; Aston CE
    Thromb Res; 2019 Oct; 182():51-55. PubMed ID: 31450008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation.
    Shin H; Cho MC; Kim RB; Kim CH; Choi NC; Kim SK; Koh EH
    J Thromb Thrombolysis; 2018 Feb; 45(2):250-256. PubMed ID: 29198080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.
    Goto E; Horinaka S; Ishimitsu T; Kato T
    Drug Metab Pharmacokinet; 2020 Feb; 35(1):151-159. PubMed ID: 32007354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
    Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
    Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
    von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
    Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
    Gosselin R; Grant RP; Adcock DM
    Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation.
    Nissan R; Spectre G; Hershkovitz A; Green H; Shimony S; Cooper L; Nakav S; Shochat T; Grossman A; Fuchs S
    Drugs Aging; 2019 Feb; 36(2):165-177. PubMed ID: 30460518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays.
    Hillarp A; Gustafsson KM; Faxälv L; Strandberg K; Baghaei F; Fagerberg Blixter I; Berndtsson M; Lindahl TL
    J Thromb Haemost; 2014 Sep; 12(9):1545-53. PubMed ID: 24965851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LC-MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column.
    Pursley J; Shen JX; Schuster A; Dang OT; Lehman J; Buonarati MH; Song Y; Aubry AF; Arnold ME
    Bioanalysis; 2014 Aug; 6(15):2071-82. PubMed ID: 25322783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study on indices of apixaban anticoagulation: A single-center prospective study.
    Komiyama M; Miyazaki Y; Wada H; Iguchi M; Abe M; Ogawa H; Akao M; Yamakage H; Satoh-Asahara N; Sunagawa Y; Morimoto T; Hasegawa K
    J Pharmacol Sci; 2018 Jun; 137(2):105-109. PubMed ID: 29866521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coagulation markers in patients with venous thromboembolism treated with 10 mg apixaban twice daily.
    Ono R; Fukushima K; Yamazaki T; Yamashita D; Takahashi H; Hori Y; Nishimura K
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Feb; 395(2):159-166. PubMed ID: 34851448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dried plasma spot as an innovative approach to therapeutic drug monitoring of apixaban: Development and validation of a novel liquid chromatography-tandem mass spectrometry method.
    Cafaro A; Stella M; Baiardi G; Barco S; Pigliasco F; Bandettini R; Nanni L; Mattioli F; Cangemi G
    J Mass Spectrom; 2024 Sep; 59(9):e5081. PubMed ID: 39187037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.